Federated Hermes
BDTX icon

Federated Hermes’s Black Diamond Therapeutics BDTX Stock Holding History

Federated Hermes’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.11K Sell
3,303
-2,060
-38% -$5.04K ﹤0.01% 1893
2026
Q1 		$11.4K Buy
5,363
+371
+7% +$882 ﹤0.01% 1832
2025
Q4 		$12.1K Sell
4,992
-187
-4% -$662 ﹤0.01% 1824
2025
Q3 		$19.6K Buy
5,179
+4,888
+1,680% +$14.3K ﹤0.01% 1814
2025
Q2 		$722 Buy
+291
New +$561 ﹤0.01% 2020
2024
Q2 		– Sell
-107
Closed -$542 – 2032
2024
Q1 		$542 Sell
107
-2,561
-96% -$10.3K ﹤0.01% 1985
2023
Q4 		$7.5K Sell
2,668
-2,498
-48% -$5.86K ﹤0.01% 1814
2023
Q3 		$14.8K Buy
5,166
+120
+2% +$442 ﹤0.01% 1789
2023
Q2 		$25.5K Sell
5,046
-8,139
-62% -$16.6K ﹤0.01% 1754
2023
Q1 		$24.9K Sell
13,185
-142,034
-92% -$326K ﹤0.01% 1795
2022
Q4 		$279K Sell
155,219
-4,329
-3% -$7.8K ﹤0.01% 1503
2022
Q3 		$270K Hold
159,548
– – ﹤0.01% 1473
2022
Q2 		$392K Sell
159,548
-875,587
-85% -$2.04M ﹤0.01% 1419
2022
Q1 		$2.87M Hold
1,035,135
– – 0.01% 929
2021
Q4 		$5.52M Hold
1,035,135
– – 0.01% 787
2021
Q3 		$8.76M Buy
1,035,135
+159,183
+18% +$1.57M 0.02% 685
2021
Q2 		$10.7M Hold
875,952
– – 0.02% 633
2021
Q1 		$21.3M Buy
875,952
+275,952
+46% +$7.44M 0.04% 477
2020
Q4 		$19.2M Buy
600,000
+125,273
+26% +$4.12M 0.04% 478
2020
Q3 		$14.4M Hold
474,727
– – 0.03% 484
2020
Q2 		$20M Buy
474,727
+74,727
+19% +$2.75M 0.05% 393
2020
Q1 		$9.98M Buy
+400,000
New +$12.2M 0.03% 479

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Federated Hermes's BDTX Position: Q2 2026 in Review

Federated Hermes reduced its Black Diamond Therapeutics (BDTX) stake by 38% in Q2 2026, selling an estimated $5.04K and leaving 3,303 shares worth $6.11K. The position accounts for ﹤0.01% of the portfolio, ranked #1893.

Federated Hermes first reported a position in BDTX in Q1 2020 and has held it in 22 quarters since. The position peaked at $21.3M in Q1 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Federated Hermes held 3,303 shares of Black Diamond Therapeutics worth $6.11K as of Q2 2026.
  • Federated Hermes sold 2,060 Black Diamond Therapeutics shares in Q2 2026, an estimated $5.04K.
  • Black Diamond Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1893 holding.
  • Federated Hermes first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 22 quarters since.
  • Federated Hermes's Black Diamond Therapeutics position peaked at $21.3M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.